Living reference work entry
The changes in pathways of clot formation and lysis, and their interactions with cells and tissues that precede or accompany cancer.
Blood coagulation dyscrasias have been linked to cancer for centuries. Tumor regression with leeching and bleeding and thrombosis complicating malignancy were among the early cues to an elegant but ruinous cybernetics. In 1867, Trousseau described “painful edema” (deep vein thrombosis, DVT) with both established and as yet undiscovered malignancies. The common occurrence of venous thromboembolism (VTE) with cancer signals poor survival and is a common cause of death in cancer patients. Compression of veins and organ damage by tumor masses, superimposed infection, surgery, radiation therapy, chemotherapy, hormonal therapy, growth factor/cytokine administration, and antiangiogenic therapy predispose to cancer-related thrombosis. Cancer-related thrombotic syndromes besides VTE include nonbacterial thrombotic (marantic; pertaining...
KeywordsCoagulation Activation Coagulation Pathway Coagulation Mechanism Occult Malignancy Epsilon Aminocaproic Acid
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- Dvorak HF, Rickles FR (2006) Malignancy and hemostasis. In: Colman RW, Marder VJ, George JN, Goldhaber SZ (eds) Hemostasis and thrombosis, basic principles and clinical practice, 5th edn. Lipincott, Williams & Wilkins, Philadelphia, pp 851–873Google Scholar
- Levine MN, Lee AYY, Kakkar AK (2006) Cancer and thrombosis. In: Colman RW, Marder VJ, George JN, Goldhaber SZ (eds) Hemostasis and thrombosis, basic principles and clinical practice, 5th edn. Lipincott, Williams & Wilkins, Philadelphia, pp 1251–1262Google Scholar
© Springer-Verlag Berlin Heidelberg 2015